- Home
- OMCL vs MLTX Comparison
OMCL vs MLTX Comparison
Compare OMCL & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | MLTX |
|---|---|---|
| Founded | 1992 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OMCL | MLTX |
|---|---|---|
| Price | $36.32 | $18.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $53.67 | $27.50 |
| AVG Volume (30 Days) | 394.2K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $875.00 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $5.95 |
| 52 Week High | $51.84 | $62.75 |
Technical Indicators
Market Signals| Indicator | OMCL | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 56.71 |
| Support Level | $35.38 | $15.37 |
| Resistance Level | $37.51 | $19.02 |
| Average True Range (ATR) | 1.43 | 1.28 |
| MACD | 0.50 | 0.15 |
| Stochastic Oscillator | 82.18 | 77.78 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.